


Anticancer agent 47

Cat. No.:	HY-146040
CAS No.:	2461795-23-1
Molecular Formula:	C ₁₉ H ₁₄ N ₂ O ₄ S
Molecular Weight:	366.39
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 47 (compound 4j) is a potent anticancer agent. Anticancer agent 47 shows antiproliferative activities. Anticancer agent 47 induces apoptosis and cell cycle arrest at G ₀ /G ₁ phase. Anticancer agent 47 shows antitumor activities in vivo ^[1] .																
In Vitro	<p>Anticancer agent 47 (compound 4j) shows antiproliferative activities with IC₅₀s of 1.6, 0.72, 7.07 μM for HepG2, A549, H596 cells, respectively^[1].</p> <p>Anticancer agent 47 (0.8, 1.6, 3.2 μM; 24 h) induces apoptosis and cell cycle arrest at G₀/G₁ phase^[1].</p> <p>Anticancer agent 47 (5 μM; 5h) significantly increases ROS production^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2, H596 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.8, 1.6, 3.2 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Induced apoptosis with the apoptotic cell rates were 14.23, 20.47 and 27.66% at 0.8, 1.6, 3.2 μM in HepG2 cell, respectively.</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.8, 1.6, 3.2 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Showed 48.54%, 49.60% and 53.00% cells were at G₀/G₁ phase at 0.6, 1.2 and 2.4 μM, respectively.</td> </tr> </table>	Cell Line:	HepG2, H596 cells	Concentration:	0.8, 1.6, 3.2 μM	Incubation Time:	24 h	Result:	Induced apoptosis with the apoptotic cell rates were 14.23, 20.47 and 27.66% at 0.8, 1.6, 3.2 μM in HepG2 cell, respectively.	Cell Line:	HepG2 cells	Concentration:	0.8, 1.6, 3.2 μM	Incubation Time:	24 h	Result:	Showed 48.54%, 49.60% and 53.00% cells were at G ₀ /G ₁ phase at 0.6, 1.2 and 2.4 μM, respectively.
Cell Line:	HepG2, H596 cells																
Concentration:	0.8, 1.6, 3.2 μM																
Incubation Time:	24 h																
Result:	Induced apoptosis with the apoptotic cell rates were 14.23, 20.47 and 27.66% at 0.8, 1.6, 3.2 μM in HepG2 cell, respectively.																
Cell Line:	HepG2 cells																
Concentration:	0.8, 1.6, 3.2 μM																
Incubation Time:	24 h																
Result:	Showed 48.54%, 49.60% and 53.00% cells were at G ₀ /G ₁ phase at 0.6, 1.2 and 2.4 μM, respectively.																
In Vivo	Anticancer agent 47 (20 mg/kg; i.v.; once every 2 days for 19 days) shows antitumor activities ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																

Animal Model:	BALB/c nude mice (HepG2 xenografts) ^[1]
Dosage:	20 mg/kg
Administration:	I.v.; once every 2 days for 19 days
Result:	Effectively inhibited tumor growth with the 58.7% tumor inhibition rate.

REFERENCES

[1]. Wu L, et al. Synthesis and biological evaluation of β -lapachone-monastrol hybrids as potential anticancer agents. Eur J Med Chem. 2020 Oct 1;203:112594.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA